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The cytoplasmic domain of human immunodeficiency virus type 1 (HIV-1) envelope (Env) transmembrane protein gp41 interacts with the viral
matrix MA protein, which facilitates incorporation of the trimeric Env complex into the virus. It is thus feasible to design an anti-HIV strategy
targeting this interaction. We herein describe that Gag expression can be downregulated by a cytoplasmic domain fusion protein of the Env
transmembrane protein, β-galactosidase (β-gal)/706–856, which contains the cytoplasmic tail of gp41 fused at the C terminus of Escherichia coli
β-gal. This mediator depleted intracellular Gag molecules in a dose-dependent manner. Sucrose gradient ultracentrifugation and confocal
microscopy revealed that Gag and β-gal/706–856 had stable interactions and formed aggregated complexes in perinuclear, intracellular sites.
Pulse-chase and cycloheximide chase analyses demonstrated that this mediator enhanced unmyristylated Gag degradation. The results demonstrate
a novel mode of HIV-1 Gag downregulation by directing Gag to an intracellular site via the interaction of Gag with a gp41 cytoplasmic domain
fusion protein.
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The assembly of human immunodeficiency virus type 1
(HIV-1), HIV-2, and simian immunodeficiency virus (SIV), all
lentiviruses, is directed by the Gag protein, which contains all of
the determinants necessary and sufficient for viral assembly and
budding (for reviews see references Freed, 1998; Garnier et al.,
1998; Sakalian and Hunter, 1998). Formation of infectious HIV
and SIV particles involves incorporation of viral envelope (Env)
glycoproteins as well as viral RNA into the nascent particles
that bud from the cell surface. During virus assembly and
morphogenesis, the Gag polyproteins assemble into a network
of “ring-like” structures at the plasma membrane; following
proteolytic cleavage of the Gag precursor, the mature capsid
(CA) protein forms a “fullerene-like” shell of the viral core
(Gelderblom et al., 1987; Nermut et al., 1994). Also, within the
maturing viral particle, the matrix (MA) protein remains in the⁎ Corresponding author. Fax: +886 2 2785 8847.
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bilayer by the myristic acid attached to its N-terminus. The basic
multimeric unit of the MA protein is a trimer (Massiah et al.,
1994; Matthews et al., 1994; Rao et al., 1995), and this model
proposes that the cytoplasmic tail of the trimeric Env is
localized to the cage hole present in the lattice-like MA structure
formed upon MA trimerization (Hill et al., 1996).
During maturation, assembly, and budding processes, Pr55
Gag complexes are present as large, intermediate multimeric
assembly complexes in the cytoplasm as well as membrane
fractions of infected cells (Ono and Freed, 1999; Paillart and
Gottlinger, 1999; Spearman et al., 1997). Further kinetic
analyses of Gag synthesis and assembly demonstrated that
newly synthesized Gag molecules rapidly form detergent-
resistant, cytoplasmic Gag complexes and that a subpopulation
of newly synthesized Gag can be chased into membrane-bound
complexes of increasing size or density over the chase period
(Tritel and Resh, 2000). Also, a major fraction of newly
synthesized Gag may undergo proteasomal degradation,
presumably due to misfolding of the Gag molecules (Schubert
et al., 2000; Tritel and Resh, 2000).
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tion facilitates recruitment of the trimeric Env complex into
buds where mature virions are released into the medium (for
reviews see references Freed, 1998; Garoff et al., 1998). The
intracellular targeting and localization properties of Gag and
Env are often affected by alterations in their counterparts
(Hermida-Matsumoto and Resh, 2000; Vincent et al., 1999),
nevertheless, Salzwedel et al. (1998) showed that retention of
the Env protein in the endoplasmic reticulum (ER) by adding an
ER retention signal to the C terminus of the protein neither
affects Gag intracellular localization nor alters Gag budding
from the plasma membrane. Other studies have also substan-
tiated the notion that interactions between the transmembrane
gp41 protein and Gag are specific for the presence of the
cytoplasmic tail of gp41 (Cosson, 1996; Vincent et al., 1999;
Wyma et al., 2000).
The cytoplasmic domain of gp41, encompassing residues
706 to 856, is characterized by the presence of three
amphipathic α-helical segments, located at residues 828–856,
770–795, and 789–815, respectively, at its C-terminus. Due to
their cytolytic effects on cell membranes, these three motifs are
referred to as the lentivirus lytic peptide (LLP)-1, LLP-2, and
LLP-3, respectively. The cytoplasmic tail has been shown to
interact with various cellular components, such as proteins
involved in the induction of apoptosis (Micoli et al., 2000; Pan
et al., 1996), the AP-1 and AP-2 clathrin–adaptor complexes
(Berlioz-Torrent et al., 1999; Boge et al., 1998; Ohno et al.,
1997; Wyss et al., 2001), and TIP47, a protein required for the
transport of mannose-6-phosphate receptors from endosomes to
the trans-Golgi network (Blot et al., 2003). Our previous studies
supported the proposal that the oligomerization and membrane-
binding abilities of the cytoplasmic domain play crucial roles in
Env assembly and virus infection (Chen et al., 1996, 1999,
2001; Lee et al., 2000). It is conceivable that Gag-cytoplasmic
tail interaction can be used as a strategic target for the design of
an anti-HIV strategy.
Since Gag is an attractive target for designing anti-HIV
strategies, it is of interest to understand whether Gag expression
can somehow be downregulated in Gag expression cells. We
demonstrate herein that Escherichia (E.) coli β-galactosidase
(β-gal) and a cytoplasmic tail fusion protein, β-gal/706–856,
acts as a novel modulator to abrogate steady-state Gag
expression via degradation. Also, the cytoplasmic tail fusion
protein specifically interacts with Gag and directs Gag to an
intracellular site. To our knowledge, this mode of down-
regulation of HIV-1 Gag expression has never been noted in
previously reported HIV dominant-negative mutants or anti-
HIV strategies. Our study also has implications in devising a
genetic anti-HIV approach to interfering with Gag maturation.
Results
Downregulation of HIV-1 Gag expression by a gp41
cytoplasmic tail fusion protein
To explore whether the interaction of the cytoplasmic tail
of gp41 with Gag can serve as a strategic target for thedevelopment of an anti-HIV-1 approach, we examined whether
a cytoplasmic domain fusion protein expressed in cells can
affect steady-state Gag expression. 293T cells were cotrans-
fected with equal amounts of pHIVgpt and pCDNA3-β-gal/
706–856. pHIVgpt encodes an HIV genome in which the env
gene is replaced by an simian virus (SV) 40 promoter-driven gpt
gene (Page et al., 1990). pCDNA3-β-gal/706–856 encodes the
entire cytoplasmic tail of the HXB2 strain Env fused to the C
terminus of the E. coli reporter protein β-gal (Chen et al., 2001).
Cotransfection with pCDNA3 or pCDNA3-β-gal was used as
negative controls. Equal volumes of cell and virion lysates were
resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (PAGE) followed by Western blotting using
mouse monoclonal antibody (Mab) 183, which is specific the
p24 CA protein. During or after virus budding, the Pr55 Gag
precursor is cleaved by the virus-encoded protease into MA
p17, CA p24, p2 (sp 1), nucleocapsid p7, p1 (sp 2), and the C-
terminal p6 domain. With β-gal/706–856 coexpression, the
intracellular levels of Pr55, an uncleaved MA and CA
intermediate (p41), and p24, which are all recognized by Mab
183, were remarkably reduced compared both to the control,
which did not express β-gal, and to β-gal coexpression (Fig.
1A, middle panel, compare lane 4 to lanes 2 and 3). The virion-
associated levels of Pr55 and its cleavage products were also
strikingly reduced in β-gal/706–856 coexpression (Fig. 1A,
middle panel, lane 9). The effect of this mediator on reduced
steady-state Gag expression was specific since β-gal/706–752,
in which the sequence spanning residues 706 to 752 of Env was
fused at the C terminus of β-gal, did not affect Gag expression
or budding (Fig. 1A, middle panel, lanes 5 and 10). When
samples were analyzed for expression of β-gal or the β-gal
fusion proteins, a similar level of β-gal/706–856 was detected
in cells compared to β-gal and β-gal/706–752 expression (Fig.
1A, top panel). β-gal/706–856 appeared to be prone to
degradation since a smaller-molecular-weight species which
co-migrated with β-gal could be detected with β-gal/706–856
coexpression (Fig. 1A, top panel, lane 4).
Effects of Gag structures on β-gal/706–856-modulated Gag
expression
To examine whether Gag processing affects β-gal/706–856-
modulated Gag expressions, 293T cells were cotransfected with
a pHIVgpt-derived pHIVgptpro− construct and each of the
pCDNA3-β-gal plasmids at a 1:1 molar ratio. Since pHIVgpt-
pro− encodes a dysfunctional protease in which the catalytic site
at residue Asp-25 of the pro gene in pHIVgpt is mutated to Asn
(Wang et al., 2000), the Pr55 precursor synthesized was not
cleaved to produce p41 or p24. Similar levels of β-gal and β-
gal/706–856 were expressed in cells (Fig. 1B). Again, β-gal/
706–856 significantly reduced the intracellular and virion-
associated Pr55 level compared to β-gal coexpression (Fig. 1B).
To study whether Gag targeting to the plasma membrane
is crucial for the downregulating effect of β-gal/706–856
on Gag expressions, pHIVgptmyr−, which encodes a Gly-to-
Ala substitution at residue 2 of MA in the env-defective
pHIVgpt backbone (Wang and Barklis, 1993), was examined.
Fig. 1. Reduced Gag expression by β-gal/706–856. 293T cells were cotransfected with each of the pCDNA3 plasmids as indicated along with pHIVgpt (A),
pHIVgptpro− (B), or pHIVgptmyr− (C), respectively, and Western blotting using Mabs β-gal, 183, and β-actin, respectively, was then performed. In (D), cells were
cotransfected with 10 μg of pHIVgptpro− and 5 μg of pRL-TK in the presence of an increasing amount of pCDNA3-β-gal/706–856 as indicated. pCDNA3-β-gal was
added to keep the total amounts of the β-gal plasmids in the transfections the same. The relative percentages of Gag in cells and virions are indicated below each of the
lanes. U.D., undetectable.
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(Fig. 1C, lane 5) since abolishment of the Pr55 myristylation
signal by this mutation severely impairs Gag targeting to the
plasma membrane, as well as virus assembly and budding
(Bryant and Ratner, 1990; Gottlinger et al., 1989; Ono and
Freed, 1999; Spearman et al., 1997; Zhou and Resh, 1996).
Nevertheless, β-gal/706–856 still greatly depleted the intracel-lular levels of Gag and its cleavage products (Fig. 1C). As
shown in Figs. 1A and B, similar amounts of β-gal and β-gal/
706–856 were detected in cells (Fig. 1C).
To further study the specific effect of β-gal/706–856 on Gag
expression and to determine whether expression of β-gal/706–
856 affects the efficiency of plasmid transfection, 293T cells
were cotransfected with fixed amounts of pHIVgptpro− and
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706–856. pRL-TK encodes a Renilla reniformis luciferase gene
under the control of the promoter of the herpes simplex virus
thymidine kinase gene. Comparable levels of luciferase activity
were detected in each transfection. Also, similar amounts of β-
gal and β-gal/706–856 were expressed in cells when equal
amounts of β-gal and β-gal/706–856 plasmids were used for
transfection (Fig. 1D, compare lanes 2 and 5). β-gal/706–856
decreased Gag expression in a dose-dependent manner
(Fig. 1D).
Depletion of both cytosolic and membrane-associated Gag
complexes by β-gal/706–856
To determine which population, the membrane-free or
membrane-associated Gag proteins in cells, is depleted by the
fusion protein, 293T cells cotransfected with pHIVgptpro− or
pHIVgptmyr− together with either the β-gal or β-gal/706–856
plasmid were subjected to a membrane flotation assay. As
previously reported (Chen et al., 2001), β-gal was predomi-
nantly located in the soluble fractions 1 to 3 while β-gal/706–
856 floated to membrane fractions 7 and 8 of the sucrose
gradient (data not shown). When coexpressed with β-gal, the
majority of myristylated Pr55 Gag molecules were located in
the membrane fractions although a small fraction of Gag could
be detected in the soluble fraction (Fig. 2, left upper panel). β-
gal/706–856 strikingly depleted both the cytosolic and
membrane-associated Myr+–Gag proteins (Fig. 2, left bottom
panel). As expected, Myr− Gag was predominantly located in
the soluble, cytosolic fractions when coexpressed with β-galFig. 2. Depletion of intracellular cytosolic and membrane-associated Gag complexes b
presence of β-gal plasmids as indicated were subjected to a membrane flotation
trichloroacetic acid, and then analyzed by Western blotting using Mab 183.(Fig. 2, right upper panel), while β-gal/706–856 significantly
depleted the Gag proteins in these soluble fractions (Fig. 2, right
bottom panel).
No measurable effects of β-gal/706–856 on Env expression and
cellular functions
To assess whether the depleting effect of β-gal/706–856 on
Gag expression was specific for Gag, the effect of this mediator
on Env expression was examined. This mediator did not greatly
affect steady-state Env expression from an HIV-1 long-
terminal-repeat (LTR)-directed env plasmid pSVE7puro (Fig.
3A), nor did it alter the steady-state Env expression from pBSX,
an SV40 promoter-driven env plasmid, even at a 1:2 molar ratio
of env to β-gal/706–856 plasmids (data not shown). In addition,
β-gal/706–856 neither altered cell viability, morphology, or
integrity upon expression in 293T cells (data not shown) nor
inhibited expression of the transfected human CD4 gene (Fig.
3B). These results collectively indicate that this mediator does
not markedly alter global cellular functions or gene expression.
Effects of a cytoplasmic tail fragment on Gag expression
To understand whether the effect of β-gal/706–856 on
depletion of Gag expression observed truly represent the effect
of the cytoplasmic tail itself, a cytoplasmic tail fragment
encoded by pRK5/706–856 as a 706–856/Flag fusion fragment
(Lee et al., 2000) was assessed. As with β-gal/706–856, this
cytoplasmic tail fragment reduced steady-state levels of Gag
expressed (Fig. 4).y β-gal/706–856. Cells cotransfected with pHIVgptpro− or pHIVgptmyr− in the
assay. After fractionation, proteins in each fraction were precipitated by cold
Fig. 3. Assessment of HIV-1 env and human CD4 gene expressions when
coexpressed with β-gal/706–856. (A) 293T cells were cotransfected with
pSVE7puro and pIIIextat in the presence of each of the pCDNA3 plasmids as
indicated. Cell lysates were assessed byWestern blotting using Mabs 902, β-gal,
or β-actin, respectively. (B) 293T cells were cotransfected with 5 μg of
pCDNA3-CD4 and 5 μg of each of the pCDNA3 plasmids. Cell lysates were
analyzed by Western blotting using SIM2, a Mab specific for CD4, and anti-β-
gal, or anti-β-actin Mab, respectively.
Fig. 4. Effect of a cytoplasmic tail fragment on Gag expression. 293T cells were
cotransfected with 10 μg of pHIVgpt together with 10 μg of pRK5 or pRK5/
706–856 as indicated. Cell and virion lysates were analyzed by Western blotting
using Mabs 183, Chessie 8, and β-actin, respectively. The relative expression
levels of Gag in cells and virions are also indicated.
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We previously demonstrated that assessment of interactions
between Gag and a cytoplasmic tail fusion protein by the
detergent-containing, sucrose gradient ultracentrifugation meth-
od as previously described by Wyma et al. (2000) can detect
authentic Env–Gag interactions (Chan et al., 2004). To further
prove the fidelity of this method in detecting stable interaction
between Gag and the cytoplasmic tail fusion protein, we
determined if stable interactions exist between the native Env
and Gag. Cell-free, immature viral particles obtained from Pr55
Gag and Env coexpression were layered onto a linear 30 to 70%(wt/vol) sucrose gradient with or without a layer of 1% Triton
X-100 placed at the top of the gradient. Upon centrifugation, the
immature virions pass through the layer of detergent and
sediment to their equilibrium density in the sucrose gradient.
gp160 and gp41 remained associated with Gag to a peak in
fractions 8–10 in a gradient lacking detergent (Fig. 5A, top
panel), representing isolation of intact viral particles. In a
gradient containing detergent, the peak of Pr55 for the immature
cores was detected in fractions 2 to 4 of the gradient (Fig. 5A,
middle panel). The majority of Env and gp41 still remained
associated with the Gag core in fractions 2–4 although some
forms of gp160 and gp41 were also detected in top fractions of
the gradient (Fig. 5A, middle panel). These top fractions of Env
might have lost their ability to interact with Gag during
treatment of the virus with Triton X-100 or ultracentrifugation.
When cell lysates containing Env alone were analyzed, gp160
and gp41 were separately detected with peaks in fraction 8 and
fractions 10 and 11, respectively (Fig. 5A, bottom panel). This
approach thus provides a readily available assay to address
detergent-resistant, molecular interactions between Gag and β-
gal/706–856.
When lysates containing β-gal and β-gal/706–856 were
analyzed, both β-gal and β-gal/706–856 were detected with a
peak at fraction 9 (Fig. 5B). When virions obtained from cells
cotransfected with pHIVgptpro− and either β-gal or β-gal/706–
856 were analyzed, a fraction of β-gal/706–856, but not β-gal,
was associated with the Gag core in bottom fractions of the
gradient (Fig. 5C). Similarly, the 706–856/Flag fragment was
Fig. 5. Analyses of viral protein–protein interactions by sucrose gradient equilibrium ultracentrifugation. (A) Examination of Gag–Env interactions. Concentrated
virions obtained from 293T cells cotransfected with pCMVgag, pSVE7puro, and pIIIextat were analyzed by sucrose gradient ultracentrifugation which did (middle
panel) or did not contain (top panel) a layer of 1% Triton X-100. Lysates containing Env were also analyzed by a sucrose gradient without detergent (bottom panel). (B)
Sucrose gradient analysis of β-gal and β-gal/706–856. Cell lysates containing β-gal or β-gal/706–856 were analyzed by sucrose gradient containing detergent. (C)
Characterization of Gag-β-gal/706–856 interactions. Virions obtained from cells cotransfected with 15 μg of pHIVgptpro− and 3.75 μg each of the β-gal or β-gal/
706–856 plasmids were analyzed by sucrose gradients containing detergent. (D) Interaction between Gag and the 706–856/Flag fragment. Virions obtained from cells
coexpressing Gag and 706–856/Flag or cell lysates containing 706–856/Flag were analyzed by sucrose gradients containing detergent. In the top and middle panels of
(A), after fractionation, viral particles in each fraction were ultracentrifuged and analyzed by Western blotting. In the bottom panels of A–D, samples in each fraction
were precipitated with trichloroacetic acid and then analyzed by Western blotting.
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bottom fractions of the gradient (Fig. 5D). These results
together indicate that the cytoplasmic tail, per se, forms a
detergent-resistant, complex with the Gag core.
Confocal microscopy of coexpressed viral proteins
Confocal immunofluorescence analyze were then performed
to assess the intracellular localization of Gag and the fusion
protein. As we previously reported (Chen et al., 2001),
overexpression of cytosolic β-gal exhibited cytoplasmicstaining (Fig. 6A, first panel) while β-gal/706–856 was
predominantly located in the perinuclear region (Fig. 6A,
second panel). Gag was localized in the entire cytoplasm (Fig.
6A, third panel). Gag and β-gal were both distributed in the
cytoplasm when coexpressed, but they were not completely
stained in the same regions (Fig. 6B, top panel). Gag and β-gal/
706–856 were colocalized as aggregated structures in the
perinuclear and cytoplasmic regions when coexpressed (Fig.
6B, bottom panel).
To determine whether Gag and β-gal/706–856 are coloca-
lized in the ER, co-staining with an antibody directed against
Fig. 6. Confocal immunofluorescence microscopy of coexpressed viral proteins. (A) HeLa cells grown on coverslips in 24-well plates were transfected with 3 μg each
of pCDNA3-β-gal, pCDNA3-β-gal/706–856, or pHIVgptpro− as indicated. Transfected cells were incubated with Mab anti-β-gal (first and second panels) and rabbit
anti-p25/p24 (third panel), respectively. After incubation with appropriate FITC-labeled secondary antibodies, cells were examined by confocal microscopy. (B) HeLa
cells were cotransfected with 1 μg each of the β-gal or β-gal/706–856 plasmid along with 1 μg of pHIVgptmyr−. Transfected cells were incubated with Mab anti-β-gal
and rabbit anti-p25/p24. After successive incubations with fluorescence-labeled secondary antibodies, cells were examined by confocal microscopy. (C) Cells were
cotransfected with 1 μg of pCDNA3-β-gal/706–856 in the presence or absence of 1 μg of pHIVgptmyr−. Transfected cells were successively incubated with anti-β-gal
Mab, rabbit anti-p25/p24, goat anti-calreticulin, and appropriate fluorescence-labeled secondary antibodies; then cells were processed for confocal microscopy.
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Gag expression, β-gal/706–856 was colocalized with calreti-
culin (Fig. 6C, top panel), indicating its localization in the ER.
When coexpressed with Gag, β-gal/706–856 was colocalized
with Gag and calreticulin as large aggregates or punctate
structures in the perinuclear or cytoplasmic regions (Fig. 6C,bottom panel), indicating that β-gal/706–856 specifically
interacts with and directs Gag to perinuclear cytoplasmic
regions. However, the ER staining pattern differed from that
when β-gal/706–856 was expressed alone (Fig. 6C), suggesting
that the coexpression of Gag and β-gal/706–856 may affect the
structures or integrity of the ER.
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We then determined the mechanism underling downregula-
tion of Gag expression by the cytoplasmic tail fusion protein.
When 293T cells cotransfected with a fixed amount of
pHIVgptmyr− in the presence of increasing amounts of β-gal
or β-gal/706–856 plasmids were metabolically labeled with
[35S]methionine for 15 min or overnight, β-gal/706–856
decreased Gag expression in a dose-dependent manner (Fig.
7A), suggesting that β-gal/706–856 inhibits Gag translation
and/or promotes Gag degradation. In vitro coupled transcrip-
tion/translation reactions using a 1:1 molar ratio of T7
promoter-driven Gag and β-gal/705–856 plasmids showed
that β-gal/705–856 did not affect Gag translation in the
presence or absence of microsomal membranes (data not
shown).
Next, a pulse-chase analysis, which assesses the turnover
rate of newly synthesized molecules, was performed. Gag was
turned over with faster kinetics when coexpressed with β-gal/
705–856 than with β-gal (Fig. 7B). In addition, chasing with a
translational inhibitor, cycloheximide (Mulder and Muesing,
2000), which monitors the turnover of preexisting proteins,
showed that the turnover rate of Gag was faster with β-gal/706–
856 coexpression than with β-gal coexpression, and that the
degree in Gag degradation was dependent on the amount of the
β-gal/706–856 plasmid used in cotransfection (Fig. 7C).
Similarly, 706–856/Flag also enhanced Gag degradation in a
time-dependent manner (Fig. 7D).
Discussion
We demonstrate herein that an HXB2 strain-derived Env
cytoplasmic tail fusion protein, β-gal/706–856, depletes
intracellular Gag molecules (Fig. 1) in a mediator dose-
dependent manner (Figs. 1D and 7A). The depletion effect of
this modulator on Gag expression was specific since this
modulator did not affect steady-state expression of Env or CD4
(Fig. 3). A cytoplasmic tail fragment, 706–856/Flag, also
reduced steady-state Gag expressions (Fig. 4). The action of the
cytoplasmic tail-mediated reduction in steady-state Gag expres-
sion proceeded via time-dependent and mediator dose-depen-
dent degradation when unmyristylated Gag was analyzed (Fig.
7). Although there is no direct evidence for the instability of
myristylated Gag, myristylated Gag was still depleted when
coexpressed with cytoplasmic tail fragments (Figs. 1A, B, and
4), it is likely that depletion of myristylated Gag by cytoplasmic
tail fragments may still occur via a degradation pathway.
The results of confocal microscopy showed that β-gal/706–
856, but not β-gal, specifically interacted with and directed Gag
to perinuclear cytoplasmic regions, where an ER marker
calreticulin also resided, to form aggregated complexes (Fig.
6). Sucrose gradient ultracentrifugation analyses also demon-
strated detergent-resistant, stable interactions between Gag and
the cytoplasmic tail fragments (Fig. 5). These results suggest
that interactions of Gag with the cytoplasmic tail fusion protein
and the targeting of Gag to an intracellular site are required for
β-gal/706–856-mediated Gag depletion.Different regions or sequences located in the C-terminal
two-thirds segment of the Env cytoplasmic domain of
primate immunodeficiency viruses have been implicated in
interactions with Gag (Celma et al., 2001; Freed and Martin,
1995, 1996; Hourioux et al., 2000; Murakami and Freed,
2000). We previously showed that fusion proteins containing
the cytoplasmic domain or each of the LLP motifs is
colocalized with the ER markers (Chen et al., 2001). The
present studies showed that β-gal/706–856 redirects Gag to
an intracellular compartment, where calreticulin is also
located, to form aggregated structures (Fig. 6). A structure
called an “aggresome” has been defined as a pericentriolar,
membrane-free, cytoplasmic inclusion composed of aggre-
gated, misfolded proteins surrounded by disorganized
filaments (Johnston et al., 1998). Formation of aggresomes
is a general cellular response when the capacity of cells to
degrade misfolded proteins is exceeded. It is likely that the
vesicles or bodies containing the cytoplasmic tail fragment
and Gag may represent aggresomes where altered Gag
structures have accumulated.
We previously showed that β-gal/706–856 is rapidly
associated with the membrane fraction after synthesis in a
pulse-chase study (data not shown). Other studies also showed
that interactions of LLP sequences with membranes proceed in a
rapid mode (Miller et al., 1993; Srinivas et al., 1992). This may
explain why Gag rapidly degrades when coexpressed with β-
gal/706–856 even during the 10-min or 15-min labeling time
(Fig. 7A) since Gag may rapidly interact with β-gal/706–856
after biosynthesis. Nevertheless, metabolically labeled and
preexisting, unlabeled Gag molecules undergo time-dependent
degradation (Figs. 7B, C, and D).
We show here that the interplay between Gag and β-gal/
706–856 can modulate Gag expression. In the context of Env
and β-gal/706–856 coexpression, β-gal/706–856 does not
affect Env synthesis (Fig. 3A), indicating that the interaction of
β-gal/706–856 with Env, presumably via cytoplasmic tail
intersubunit interactions, does not destabilize the Env-β-gal/
706–856 complex. However, in the context of Gag and β-gal/
706–856 coexpression, the structurally altered Gag-β-gal/706–
856 complexes formed after biosynthesis are unstable and
subsequently degrade intracellularly by an as yet uncharacter-
ized intracellular degradation pathway. Alternatively, β-gal/
706–856 may somehow interfere with the multimerization,
assembly, or intracellular trafficking processes of Gag,
rendering Gag assembly intermediate complexes susceptible
to degradation.
In the present study, we demonstrate a novel mode of
downregulation of HIV-1 Gag expression by a cytoplasmic
domain fusion protein, which can serve as a module to
control the expressions of Gag, thus regulating HIV-1 Gag
assembly/budding. Since Gag expression is crucial for
morphogenesis and the formation of an infectious virus,
our study also has implications for diverting Gag from its
normal maturation and assembly/budding pathway to an
intracellular degradation route. The results may help design
a genetic antiviral strategy to control the maturation process
of HIV-1 Gag protein.
Fig. 7. Promotion of Gag degradation by cytoplasmic tail fusion proteins. (A) 293T cells were cotransfected with 5 μg of pHIVgptmyr− together with the β-gal or β-
gal/706–856 plasmid at different molar ratios of Gag to β-gal or β-gal/706–856 plasmids as indicated. pCDNA3 was added to adjust the total amounts of DNA in all
transfections to be the same. Transfected cells were metabolically labeled with [35S]methionine for 15 min (top panel) or overnight (bottom panel). Cell lysates were
immunoprecipitated with AIDS patients' antisera preadsorbed onto protein A-Sepharose 4B beads, followed by SDS-PAGE. (B) 293T cells cotransfected with 5 μg of
pHIVgptmyr− along with 2 μg each of the β-gal and β-gal/706–856 plasmids were metabolically labeled for 10 min and then chased with excess cold methionine for
different time points. Cell lysates were immunoprecipitated, and the immune complexes were resolved by SDS-PAGE (top panel). The dried gels were scanned and
quantitated as described under Materials and methods. The relative percentages of the total radioactivity of Gag proteins at each chase time to that of the Gag proteins at
chase time zero were plotted (bottom panel). (C) Cells were cotransfected with 5 μg of pHIVgptmyr− and the indicated amounts of pCDNA3-β-gal/706–856.
pCDNA3-β-gal was added to the transfection mixtures to maintain the same amount of total plasmids in each transfection. A cycloheximide chase was performed, and
cell lysates obtained at different time points after the chase were analyzed by Western blotting. Photos of ECL blots were scanned and quantitated, and the total
intensities of Gag for different chase periods are expressed as percentages of those of Gag at a chase time of zero. (D) Cells were cotransfected with 5 μg of
pHIVgptmyr− and 2 μg of pRK5 (lanes 1 to 3) or pRK5/706–856 (lanes 4 to 6), and the cycloheximide chase was performed as described in panel C.
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Cells, hybridomas, and antibodies
HEK293T and HeLa cells were cultured in Dulbecco's
modified Eagle's medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS). Hybridoma 902, Chessie
8, and 183 (clone H12-5C) were described previously (Lee et
al., 2002). SIM2 is a hybridoma producing a Mab that
recognizes human CD4. All of these hybridomas were
maintained in RPMI-1640 containing 10% FBS. Rabbit
antiserum to HIV-1 p25/p24 was previously described (Chen
et al., 1998). Mabs directed against β-gal and β-actin were
purchased from Promega and Sigma, respectively. Affinity-
purified goat antibody directed against the C-termini of human
calreticulin was obtained from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA).
Construction of plasmids
pCDNA3-CD4 was constructed by cloning the EcoRI–XbaI
fragment isolated from a human CD4 plasmid, pBS-CD4 (Shaw
et al., 1989), into the corresponding sites in pCDNA3
(Invitrogen, Carlsbad, CA).
Plasmid DNA transfection
293T cells were transfected with plasmids using a standard
calcium phosphate coprecipitation method as previously
described (Chen et al., 1998, 1999). For Env expression,
293Tcells were cotransfected with 5 μg of pSVE7puro and 3 μg
of an HIV-1 LTR-directed Tat expression plasmid pIIIextat in
the presence of 5 μg of pCDNA3-β-gal/706–856. When the
effect of β-gal/706–856 on Gag expression from pHIVgpt
clones was examined, 10 μg each of the pCDNA3-β-gal/706–
856 and pHIVgpt clones was used for cotransfection unless
otherwise indicated. For sucrose gradient ultracentrifugation,
293T cells were transfected with 10 μg of pCMVgag in the
presence of 10 μg of pSVE7puro and 3 μg of pIIIextat.
Alternatively, cells were cotransfected with pHIVgptpro− in the
presence of pCDNA3-β-gal or pCDNA3-β-gal/706–856 at the
plasmid ratios indicated in each experiment. HeLa cells were
transfected with plasmid DNAs by the lipofectamine transfec-
tion method (Life Technologies, Rockville, MD).
Virus preparation and Western blot analysis
Two days after transfection, cell-free virions were isolated
through a 20% (wt/wt) sucrose cushion, and equal volumes
of cell and viral lysates were analyzed by SDS-PAGE and
Western blotting. The membrane blots were incubated with
appropriate primary and secondary antibodies followed by
enhanced chemiluminescent (ECL) detection. For quantita-
tion, ECL photos of the blots within the linear range of the
film were scanned using a Microtek ScanMarker 8700
(Carson, CA) and quantitated using MetaMorph software
(Universal Imaging, Downing Town, PA). The relativepercentages of Gag levels in cells and virions are shown
below each lane of the Western blots.
Membrane flotation assay and isolation of HIV-1 core
structures
For membrane flotation, washed transfected cells were
sonicated twice in 0.5 ml of hypotonic TE buffer (10 mM Tris–
HCl, pH 7.5, containing 1 mM EDTA) supplemented with a
complete protease inhibitor cocktail (Roche Molecular Bio-
chemicals; Mannheim, Germany) and 10% (wt/vol) sucrose on
ice using an Ultrasonic Processor Model W-375 (Ultrasonics;
Farmingdale, NY) with output power of 20%–30%, each time
for 15 s. After centrifugation at 1000 × g and 4 °C for 10 min,
the postnuclear fractions were subjected to the membrane
flotation assay as previously described (Chen et al., 2001).
Briefly, 0.25 ml of postnuclear supernatants were mixed with
1.25 ml of 85.5% (wt/vol) sucrose, and placed at the bottom of a
Beckman SW41 ultracentrifuge tube, and then 7 ml of 65% (wt/
vol) sucrose and 3.25 ml of 6% (wt/vol) sucrose (all prepared in
TE buffer) were successively loaded into the tube. The gradients
were centrifuged at 100,000 × g for 18 h at 4 °C. After
ultracentrifugation, samples were fractionated from the bottom
of the gradients, and 1.2 ml per fraction was collected. Immature
cores were isolated from cell-free, concentrated viruses
according to a previously described procedure (Wyma et al.,
2000) except that 0.45 ml of 15% sucrose (wt/vol) containing
1% Triton X-100 was overlaid on the top of the 30% to 70%
(wt/vol) linear density sucrose gradients (Chan et al., 2004). The
gradients were centrifuged at 100,000 × g for 16 h at 4 °C. After
fractionation, the samples in each fraction were diluted to a total
volume of 4 ml with STE buffer (10 mM Tris–HCl, pH 7.4,
containing 100 mM NaCl and 1 mM EDTA) and then
centrifuged at 50,000 rpm and 4 °C for 30 min in an SW60
rotor to pellet the viruses. Alternatively, samples were
precipitated with 10% cold trichloroacetic acid. The viral
proteins were then analyzed by Western blotting.
Confocal immunofluorescence microscopic studies
Transfected HeLa cells were fixed by 4% paraformaldehyde,
permeabilized by 0.25% Triton X-100, and then separately
incubated with the appropriate primary antibodies. After
successive incubation with 1:100 dilutions of fluorescein
isothiocyanate (FITC)-, tetramethylrhodamine isothiocyanate-,
and Cy5-conjugated secondary antibodies directed against each
species from which the primary antibodies were generated, the
immunostained cells were analyzed by confocal microscopy as
previously described (Chen et al., 2001).
Metabolic labeling, pulse-chase, and immunoprecipitation
One day after transfection, 293T cells were metabolically
labeled with [35S]methionine for the time as indicated or
labeled for 30 min and chased with excess cold methionine
as previously described (Lee et al., 2002). Cell lysates were
immunoprecipitated with pooled AIDS patients' antisera
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washed, and separated by SDS-PAGE followed by fluorogra-
phy as previously described (Chan et al., 2004). The dried gels
in Fig. 7B were scanned and quantitated using a Packard
Instant Imager, model A202401 (Packard Instrument; Mer-
iden, CT) for the radioactivity of the Pr55, p41, and p24
species. Pr55, MA, and CA of the HXB2 virus contain 16, 1,
and 11 Met residues, respectively. The radioactivities of the
Pr55, p41, and p24 species were calibrated by multiplying the
radioactivity of each species by factors of 16/16, 16/12, and
16/11, respectively.
Cycloheximide chase
Sixteen hours after transfection, 293T cells were treated with
cycloheximide (Sigma) at a final concentration of 100 μg/ml.
Cells lysates were harvested at sequential time points after
treatment, and analyzed by Western blotting.
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